CELsignia

FACT 1: Herceptin ® + Perjeta ® + AC-THP in Early-Stage HER2-Negative Breast Cancer Patients Selected with the CELsignia HER2 Activity Test (NCT03412643/FB-12)

FACT 2: Nerlynx ® + Paclitaxel + Carboplatin in Early-Stage Triple-Negative Breast Cancer Patients Selected with the CELsignia HER2 Activity Test (NCT03812393)

FACT 3: Xalkori ® + Vizimpro ® in Metastatic HER2-Negative Breast Cancer Patients Selected with the CELsignia MP Activity Test for HER2 and c-Met  (NCT# not yet assigned)

FACT 4: Nerlynx ® + Faslodex ® in Metastatic HR-Positive Breast Cancer Patients Selected with the CELsignia HER2 Activity Test (NCT# not yet assigned)

FACT 6: Tabrecta ® + Nerlynx ® in Metastatic HER2-Negative Breast Cancer Patients Selected with the CELsignia MP Activity Test for HER2 and c-Met (NCT# not yet assigned)

Gedatolisib – Celcuity

Phase 1b study of Gedatolisib + Ibrance ®+ Endocrine Therapy in 1L/2L Metastatic ER-Positive, HER2-Negative Breast Cancer Patients  (NCT02684032)

Gedatolisib – Investigator Sponsored

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER2-Positive Metastatic Breast Cancer (NCT03698383)